(Q45882434)

English

B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

1 reference

based on heuristic

inferred from title

8

object named as

J M Lusher

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

author name string

C M Kessler

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

J C Gill

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

G C White

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

A Shapiro

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

S Arkin

5

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

D A Roth

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

X Meng

7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

11

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

84-91

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

The use of recombinant factor VIII products in previously treated patients with hemophilia A: pharmacokinetics, efficacy, safety, and inhibitor development

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Evolving perspectives in product safety for haemophilia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

The future of recombinant coagulation factors.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

The pharmacokinetics of clotting factor therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

A simple and accurate microplate assay for the determination of factor VIII activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

An exact confidence interval from untransformed data for the ratio of two formulation means

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Potency estimation of recombinant factor VIII: effect of assay method and standard

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

A blinded in vitro study with Refacto mock plasma samples: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Pharmacokinetics of factor VIII and factor IX

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Influence of phospholipids on the assessment of factor VIII activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Meta-analysis on the effectiveness of B-domain deleted factor VIII for prophylaxis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Controversial use of meta-analysis for factor VIII pharmacokinetic data

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - another rebuttal

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Comparative effectiveness of full‐length and B‐domain deleted factor VIII for prophylaxis – a meta‐analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01068.X

21 January 2018

Identifiers

10.1111/J.1365-2516.2005.01068.X

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/15810908

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45882434&oldid=2088341813"